Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

ABSTRACT:

Background & aims

Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function.

Methods

We examined the US Food and Drug Administration's database of reported adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glucagon-like peptide-1 mimetic exenatide, from 2004-2009; data on adverse events associated with 4 other medications were compared as controls. The primary outcomes measures were rates of reported pancreatitis, pancreatic and thyroid cancer, and all cancers associated with sitagliptin or

SUBMITTER: Elashoff M 

PROVIDER: S-EPMC4404515 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature